ATE464890T1 - Eine pharmazeutische zusammensetzung zur behandlung von pathologien, die durch die allgemeine immunantwort verursacht werden - Google Patents

Eine pharmazeutische zusammensetzung zur behandlung von pathologien, die durch die allgemeine immunantwort verursacht werden

Info

Publication number
ATE464890T1
ATE464890T1 AT06425206T AT06425206T ATE464890T1 AT E464890 T1 ATE464890 T1 AT E464890T1 AT 06425206 T AT06425206 T AT 06425206T AT 06425206 T AT06425206 T AT 06425206T AT E464890 T1 ATE464890 T1 AT E464890T1
Authority
AT
Austria
Prior art keywords
treatment
pharmaceutical composition
immune response
pathologies caused
general immune
Prior art date
Application number
AT06425206T
Other languages
English (en)
Inventor
Valle Francesco Della
Valle Maria Federica Della
Gabriele Marcolongo
Gianpiero Ravagnan
Marzo Vincenzo Di
Original Assignee
Epitech Group Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitech Group Srl filed Critical Epitech Group Srl
Application granted granted Critical
Publication of ATE464890T1 publication Critical patent/ATE464890T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06425206T 2006-03-28 2006-03-28 Eine pharmazeutische zusammensetzung zur behandlung von pathologien, die durch die allgemeine immunantwort verursacht werden ATE464890T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06425206A EP1844784B1 (de) 2006-03-28 2006-03-28 Eine Pharmazeutische Zusammensetzung zur Behandlung von Pathologien, die durch die allgemeine Immunantwort verursacht werden

Publications (1)

Publication Number Publication Date
ATE464890T1 true ATE464890T1 (de) 2010-05-15

Family

ID=36741312

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06425206T ATE464890T1 (de) 2006-03-28 2006-03-28 Eine pharmazeutische zusammensetzung zur behandlung von pathologien, die durch die allgemeine immunantwort verursacht werden

Country Status (8)

Country Link
US (2) US20070270496A1 (de)
EP (1) EP1844784B1 (de)
JP (1) JP5253750B2 (de)
AT (1) ATE464890T1 (de)
CA (1) CA2582027C (de)
DE (1) DE602006013787D1 (de)
ES (1) ES2344920T3 (de)
HK (1) HK1110016A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20080019A1 (it) * 2008-02-11 2009-08-12 Glures S R L Formulazioni comprendenti piceide e resveratrolo atte a prevenire e inibire la perossidazione lipidica.
FR2933871B1 (fr) * 2008-07-18 2012-12-14 Yvery Formulation destinee a ameliorer la biodisponibilite d'une molecule hydrophobe
CN102307568B (zh) 2009-02-04 2014-12-24 帝斯曼知识产权资产管理有限公司 白藜芦醇组合物
GB0903688D0 (en) * 2009-03-03 2009-04-15 Agentis Suppliments Composition
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
FR2947452B1 (fr) * 2009-07-01 2012-04-20 Fabre Pierre Dermo Cosmetique L-serine et/ou l-asparagine et/ou l-valine pour prevenir et/ou au traiter des reactions inflammatoires de la peau.
US8470373B2 (en) * 2009-09-07 2013-06-25 Epitech Group S.R.L. Composition containing ultra-micronized palmitoyl-ethanolamide
EP2444078B1 (de) * 2010-10-04 2017-09-13 EPITECH GROUP S.p.A. Verwendung von amiden von mono- und dicarboxylsäuren bei der behandlung von nierenkrankheiten
EP2455066B1 (de) * 2010-11-08 2018-10-17 EPITECH GROUP S.p.A. Pharmakologische Zubereitung zur topischen Anwendung enthaltend N-Palmitoyl-Vanillamid
KR20140020840A (ko) 2010-11-18 2014-02-19 이쉐믹스 엘엘씨 허혈성 손상을 치료하기 위한 리포일 화합물 및 이의 용도
ES2428665B1 (es) * 2012-05-04 2014-10-01 Universidad De Valladolid Composición para su uso en el tratamiento y/o prevención de la inflamación, el estrés oxidativo y la neovascularización ocular
JP5955750B2 (ja) * 2012-11-20 2016-07-20 株式会社東洋新薬 皮膚外用剤
US20160008301A1 (en) * 2014-07-08 2016-01-14 Epitech Group S.R.L. Use of Adelmidrol in the Treatment of Epithelial Dysfunctions
CN106714792A (zh) * 2014-08-08 2017-05-24 R·米利亚乔 用于治疗炎症性和过敏性病理学的脂肪酸和十六酰胺乙醇的混合物
ITUB20154849A1 (it) * 2015-10-30 2017-04-30 Epitech Group S P A ADELMIDROL PER L'USO NELLE PATOLOGIE CARATTERIZZATE DA INSUFFICIENTE AGONISMO DEL RECETTORE PPAR-gamma
CN105418698B (zh) * 2015-12-21 2018-04-27 上海市第七人民医院 一种酰胺乙氧基-β-D-葡萄糖苷类化合物及其制备方法和应用
DK3615023T3 (da) 2017-04-25 2023-09-25 Ischemix Llc Lipoyl-glu-ala til behandlingen af neurodegenerativ skade forårsaget af traumatisk hjerneskade
SG10201807034XA (en) 2017-09-05 2019-04-29 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease
IT201800003912A1 (it) * 2018-03-26 2019-09-26 Innovet Italia Srl N-palmitoil-d-glucosamina in forma micronizzata
US10688042B1 (en) * 2019-10-15 2020-06-23 Antonino Cavallaro Topical gel for alleviating food cravings and method of making same
CN112110966B (zh) * 2020-10-14 2023-10-03 牛倩 白藜芦醇糖苷类衍生物、制备和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1252866B (it) * 1991-12-31 1995-06-28 Lifegroup Spa N-acilderivati di aminoalcooli con acidi policarbossilici atti alla modulazione dei mastociti nei processi infiammatori su base neuroimmunogenica
US5506224A (en) * 1991-12-31 1996-04-09 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes
IT1252865B (it) * 1991-12-31 1995-06-28 Lifegroup Spa N-acilderivati di aminoalcooli attivi come autocoidi locali ed utilizzabili nella terapia dei processi autoimmuni
US5618842A (en) * 1991-12-31 1997-04-08 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols with polycarboxylic acids able to modulate mast cells in inflammatory processes having neuroimmunogenic origin
IT1271624B (it) * 1994-03-21 1997-06-04 Lifegroup Spa Derivati glucosidici di n-acil alchilamine capaci di esercitare effetto o neuroprotettivo utilizzabili nelle patologie acute e croniche del sistema nervoso centrale correlate ad eccitotossicita'
PE20010540A1 (es) * 1999-07-30 2001-05-15 Procter & Gamble Composicion de fitoalexinas estilbenicas util para la profilaxis y tratamiento de sintomas asociados con el resfriado y enfermedades similares a la influenza
AU7948400A (en) * 1999-10-19 2001-04-30 Taisho Pharmaceutical Co., Ltd. N-cycloalkyl thiooxamide derivatives
IT1317034B1 (it) * 2000-05-30 2003-05-26 Istituto Di Medicina Speriment Metodo di estrazione di prodotti ad attivita' farmaceutica da piantespermatofite, prodotti cosi' ottenuti e loro impiego in medicina, in
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
WO2003077900A1 (en) * 2002-03-14 2003-09-25 Prevention, L.L.C. A unifying mechanism and methods to prevent cancer and neurodegenerative diseases

Also Published As

Publication number Publication date
JP2007262068A (ja) 2007-10-11
US20070270496A1 (en) 2007-11-22
US20110288037A1 (en) 2011-11-24
JP5253750B2 (ja) 2013-07-31
CA2582027C (en) 2016-05-17
EP1844784A1 (de) 2007-10-17
EP1844784B1 (de) 2010-04-21
ES2344920T3 (es) 2010-09-09
CA2582027A1 (en) 2007-09-28
HK1110016A1 (en) 2008-07-04
DE602006013787D1 (de) 2010-06-02

Similar Documents

Publication Publication Date Title
ATE464890T1 (de) Eine pharmazeutische zusammensetzung zur behandlung von pathologien, die durch die allgemeine immunantwort verursacht werden
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
DE60327745D1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
TW200716208A (en) Modified and immediate release memantine bead formulation
WO2007070052A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
MX2008009947A (es) Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos.
CY1108342T1 (el) Ανοσορρυθμιστικοι ολιγοσακχαριτες
TR200500221T2 (tr) Farmasötik Maddeler Olarak Bisiklik Amino Asitler
BRPI0813320A2 (pt) Fração lipídica, e, produto farmacêutico ou nutricional
WO2008052173A3 (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
MY172157A (en) Thioninium compounds and their use
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
ATE506957T1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
BRPI0513647A (pt) derivados de ácidos 1-fenilalcanocarboxìlicos para o tratamento de doenças neurodegenerativas
WO2009104184A3 (en) Extracts of sclerocarya birrea
EA200801977A1 (ru) Способ получения r-энантиомера n-карбамоилметил-4r-фенил-2-пирролидона
JP2006325497A5 (de)
DE602006015338D1 (de) Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen
TH81163A (th) องค์ประกอบทางเภสัชกรรม
TH108942A (th) เกลือของตัวยับยั้งเอนไซม์ชนิดใหม่นอกจากนั้นที่เปลี่ยนแองจิโอเทนซินด้วยกรดตัวให้ no กระบวนการเตรียมเกลือชนิดเหล่านั้นและองค์ประกอบที่เป็นเภสัชภัณฑ์ที่มีเกลือชนิดเหล่านั้น
TH74241S (th) เตียงนอน
TH82385A (th) วิธีการสำหรับรักษาหรือป้องกันการอักเสบที่เกิดขึ้นกับทั้งระบบในเด็กอ่อนที่เลี้ยงด้วยนมผสมตามสูตร
TH78677A (th) อนุพันธ์ที่เกิดจากการรวมตัวของไพราโซล การเตรียมสารนั้น และการใช้สารนั้นในการรักษาโรค
TH87394S (th) ที่นั่ง

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1844784

Country of ref document: EP